Time filter

Source Type

Sychev D.V.,Russian Academy of Medical Sciences | Ignatyev I.V.,Research Center for Expert Evaluation of Objects of Medical Use | Emelyanov N.V.,Research Center for Expert Evaluation of Objects of Medical Use | Milovanova V.V.,Research Center for Expert Evaluation of Objects of Medical Use | And 4 more authors.
Bulletin of Experimental Biology and Medicine | Year: 2012

The study included 52 patients at a high risk of thromboembolic complications, with permanent atrial fibrillation. All patients were treated with acenocoumarol for 6 months and the incidence of hemorrhages was evaluated in all of them. All patients were genotyped by CYP2C9 and VKORC1. The presence of CYP2C9*2 and CYP2C9*3 alleles of CYP2C9 locus and AA genotype of VCORC1 gene polymorphic G-1639(3673)A marker was not associated with the development of hemorrhages under conditions of acenocoumarol treatment (p=0.144 for CYP2C9, p=0.809 and 0.918 for VCORC1 in the total group and subgroup of patients with CYP2C9*1/*1 genotype, respectively). The search for other genetic markers of acenocoumarol efficiency and safety is needed for predicting the risk of hemorrhages during this treatment. © 2012 Springer Science+Business Media New York.

Loading Research Center for Expert Evaluation of Objects of Medical Use collaborators
Loading Research Center for Expert Evaluation of Objects of Medical Use collaborators